| MeSH term | MeSH ID | Detail |
|---|---|---|
| Enterobacteriaceae Infections | D004756 | 5 associated lipids |
| Neoplasms, Glandular and Epithelial | D009375 | 12 associated lipids |
Total
2
Paclitaxel
Paclitaxel is a lipid of Prenol Lipids (PR) class. Paclitaxel is associated with abnormalities such as Multiple Sulfatase Deficiency Disease, Peripheral Neuropathy, Pulmonary Embolism, Painful Bladder Syndrome and athymia. The involved functions are known as synergism, Metabolic Inhibition, Drug Efflux, Disease regression and Oxidation. Paclitaxel often locates in Back, Hepatic, Microtubules, Head and Cytoskeleton. The associated genes with Paclitaxel are CDAN1 gene, IMPACT gene, ABCB1 gene, BCL2 gene and P4HTM gene. The related lipids are Liposomes. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of Paclitaxel, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Paclitaxel?
Paclitaxel is suspected in athymia, Multiple Sulfatase Deficiency Disease, Peripheral Neuropathy, Pulmonary Embolism, Painful Bladder Syndrome, Neuropathy and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Paclitaxel
PubChem Associated disorders and diseases
What pathways are associated with Paclitaxel
Lipid pathways are not clear in current pathway databases. We organized associated pathways with Paclitaxel through full-text articles, including metabolic pathways or pathways of biological mechanisms.
Related references are published most in these journals:
| Pathway name | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Paclitaxel?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Paclitaxel?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Paclitaxel?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Paclitaxel?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Paclitaxel?
Xenograft Model
Xenograft Model are used in the study 'The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein.' (Wang E et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with Paclitaxel
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Svenson S | What nanomedicine in the clinic right now really forms nanoparticles? | 2014 Mar-Apr | Wiley Interdiscip Rev Nanomed Nanobiotechnol | pmid:24415653 |
| Bevis KS et al. | Combination therapy with paclitaxel, carboplatin and megestrol acetate for the management of advanced stage or recurrent carcinoma of the endometrium: a phase II study. | 2014 Mar-Apr | J Reprod Med | pmid:24724218 |
| Hahn A et al. | Neoadjuvant chemotherapy for breast cancer with weekly nab-paclitaxel followed by epirubicin and cyclophosphamide--results of a case series. | 2014 Mar-Apr | In Vivo | pmid:24632979 |
| Ferrari LA et al. | Are antineoplastic drug acute hypersensitive reactions a submerged or an emergent problem? Experience of the Medical Day Hospital of the Fondazione IRCCS Istituto Nazionale Tumori. | 2014 Jan-Feb | Tumori | pmid:24675484 |
| Chen Y et al. | Comparison of salvage chemoradiation versus salvage surgery for recurrent esophageal squamous cell carcinoma after definitive radiochemotherapy or radiotherapy alone. | 2014 Feb-Mar | Dis. Esophagus | pmid:23088212 |
| Liu J et al. | Maintenance therapy with autologous cytokine-induced killer cells in patients with advanced epithelial ovarian cancer after first-line treatment. | 2014 Feb-Mar | J. Immunother. | pmid:24509174 |
| Lee NY et al. | Pharmacokinetics, placenta, and brain uptake of paclitaxel in pregnant rats. | 2014 | Cancer Chemother. Pharmacol. | pmid:24638863 |
| Fernández-Peralbo MA et al. | LC-MS/MS quantitative analysis of paclitaxel and its major metabolites in serum, plasma and tissue from women with ovarian cancer after intraperitoneal chemotherapy. | 2014 | J Pharm Biomed Anal | pmid:24447964 |
| Liistro F et al. | Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: the DEBATE-ISR study. | 2014 | J. Endovasc. Ther. | pmid:24502477 |
| Zhang J et al. | Phase II study of low-dose paclitaxel with timed thoracic radiotherapy followed by adjuvant gemcitabine and carboplatin in unresectable stage III non-small cell lung cancer. | 2014 | Lung Cancer | pmid:24246506 |
| Alfonso F et al. | Neoatherosclerosis after paclitaxel-coated balloon angioplasty for in-stent restenosis. | 2014 | Circulation | pmid:24566068 |
| Yang YI et al. | RSF1 is a positive regulator of NF-κB-induced gene expression required for ovarian cancer chemoresistance. | 2014 | Cancer Res. | pmid:24566868 |
| Amos LA and Löwe J | The subtle allostery of microtubule dynamics. | 2014 | Nat. Struct. Mol. Biol. | pmid:24896811 |
| Watanabe T et al. | Integrity of stent polymer layer after drug-eluting stent implantation: in vivo comparison of sirolimus-, paclitaxel-, zotarolimus- and everolimus-eluting stents. | 2014 | Cardiovasc Interv Ther | pmid:23818255 |
| Guo HQ et al. | β-Elemene, a compound derived from Rhizoma zedoariae, reverses multidrug resistance mediated by the ABCB1 transporter. | 2014 | Oncol. Rep. | pmid:24284783 |
| Lee K et al. | Effect of coumarin derivative-mediated inhibition of P-glycoprotein on oral bioavailability and therapeutic efficacy of paclitaxel. | 2014 | Eur. J. Pharmacol. | pmid:24252806 |
| Gupta N et al. | First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel. | 2014 | Int J Nanomedicine | pmid:24399877 |
| Sempkowski M et al. | Liposome-based approaches for delivery of mainstream chemotherapeutics: preparation methods, liposome designs, therapeutic efficacy. | 2014 | Crit Rev Oncog | pmid:25271431 |
| Imano M and Okuno K | Treatment strategies for gastric cancer patients with peritoneal metastasis. | 2014 | Surg. Today | pmid:23677598 |
| Xu WS et al. | Furanodiene presents synergistic anti-proliferative activity with paclitaxel via altering cell cycle and integrin signaling in 95-D lung cancer cells. | 2014 | Phytother Res | pmid:23554049 |